These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7918304)

  • 1. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects.
    Ferrières J; Sing CF; Roy M; Davignon J; Lussier-Cacan S
    Arterioscler Thromb; 1994 Oct; 14(10):1553-60. PubMed ID: 7918304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia.
    Bredie SJ; Vogelaar JM; Demacker PN; Stalenhoef AF
    Atherosclerosis; 1996 Oct; 126(2):313-24. PubMed ID: 8902157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect.
    Bétard C; Kessling AM; Roy M; Davignon J
    Atherosclerosis; 1996 Jan; 119(1):43-55. PubMed ID: 8929255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins.
    Gómez-Coronado D; Alvarez JJ; Entrala A; Olmos JM; Herrera E; Lasunción MA
    Atherosclerosis; 1999 Nov; 147(1):167-76. PubMed ID: 10525138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of lipid level variability in French-Canadian children with familial hypercholesterolemia.
    Lambert M; Assouline L; Feoli-Fonseca JC; Brun N; Delvin EE; Lévy E
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):979-84. PubMed ID: 11397707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
    Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
    Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia.
    Carmena-Ramón R; Real JT; Ascaso JF; Ordovás JM; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):7-13. PubMed ID: 10812582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.
    Ferrières J; Lambert J; Lussier-Cacan S; Davignon J
    Circulation; 1995 Aug; 92(3):290-5. PubMed ID: 7634440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia.
    Gylling H; Aalto-Setälä K; Kontula K; Miettinen TA
    Arterioscler Thromb; 1991; 11(5):1368-75. PubMed ID: 1911722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
    Carmena R; Roederer G; Mailloux H; Lussier-Cacan S; Davignon J
    Metabolism; 1993 Jul; 42(7):895-901. PubMed ID: 8345800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
    García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
    Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia.
    Björn Lundahl ; Leren TP; Ose L; Hamsten A; Karpe F
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1784-8. PubMed ID: 10894817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia.
    Friedlander Y; Leitersdorf E
    Genet Epidemiol; 1996; 13(2):159-77. PubMed ID: 8722744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of apoE gene polymorphism on Lp(a) concentrations depend on the size of apo(a): a study of 466 white men.
    Klausen IC; Gerdes LU; Hansen PS; Lemming L; Gerdes C; Faergeman O
    J Mol Med (Berl); 1996 Nov; 74(11):685-90. PubMed ID: 8956154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado.
    Kamboh MI; Aston CE; Hamman RF
    Atherosclerosis; 1995 Jan; 112(2):145-59. PubMed ID: 7772075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
    De Knijff P; Stalenhoef AF; Mol MJ; Gevers Leuven JA; Smit J; Erkelens DW; Schouten J; Frants RR; Havekes LM
    Atherosclerosis; 1990 Jul; 83(1):89-97. PubMed ID: 2390138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
    Carmena R; Lussier-Cacan S; Roy M; Minnich A; Lingenhel A; Kronenberg F; Davignon J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):129-36. PubMed ID: 8548413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.